Initiator Pharma
Innovative drugs targeting unmet needs in the central and peripheral nervous system.
| Date | Investors | Amount | Round |
|---|---|---|---|
| investor | €0.0 | round | |
| investor | €0.0 | round | |
* | SEK20.0m | Secondary | |
| Total Funding | 000k | ||
| EUR | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
Source: Company filings or news article, Equity research estimates
Related Content
Initiator Pharma A/S is a Danish clinical-stage life science company focused on developing innovative drugs that address key unmet medical needs within the central and peripheral nervous system. The company operates in the pharmaceutical industry, specifically targeting conditions such as erectile dysfunction and Trigeminal Neuralgia, a severe neuropathic pain condition. Initiator Pharma's portfolio includes five projects, with three in clinical development and two in preclinical stages. The clinical programs include IP2018 and pudafensine for treating erectile dysfunction of psychogenic and organic origin, respectively, and IPTN2021 for Trigeminal Neuralgia.
Initiator Pharma's business model revolves around identifying promising drug candidates in late preclinical and early clinical development stages. The company aims to progress these candidates toward the market in a cost-effective and timely manner, benefiting both patients in need of improved medical therapies and shareholders. Revenue is generated through the development and potential commercialization of these drug candidates, as well as through partnerships and collaborations with other pharmaceutical companies.
Keywords: monoamine reuptake inhibitors, erectile dysfunction, Trigeminal Neuralgia, neuropathic pain, clinical-stage, life science, drug development, central nervous system, peripheral nervous system, innovative therapies.